- Home
- SAFE vs GERN Comparison
SAFE vs GERN Comparison
Compare SAFE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | GERN |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SAFE | GERN |
|---|---|---|
| Price | $13.51 | $1.28 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 3 |
| Target Price | ★ $19.00 | $2.17 |
| AVG Volume (30 Days) | 312.0K | ★ 9.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | 7.43 | ★ 51.85 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | $1,065,000.00 |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $4.31 | $43.75 |
| P/E Ratio | $16.04 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $1.04 |
| 52 Week High | $17.45 | $2.01 |
Technical Indicators
Market Signals| Indicator | SAFE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 28.66 | 37.29 |
| Support Level | $13.36 | $1.24 |
| Resistance Level | $15.59 | $1.32 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 17.81 | 4.29 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.